TickerFacts.

Alpha Teknova, Inc. (TKNO): Revenue

Annual figures by period end, from SEC filings.

$40.52M
Year ended 2025-12-31
$43.70M
Trailing 12 months to 2026-06-30
-0.7%
3-year compound annual growth
+5.3%
5-year compound annual growth
$41.42M2020-12-31: $31.30M2021-12-31: $36.89M2022-12-31: $41.42M2023-12-31: $36.68M2024-12-31: $37.74M2025-12-31: $40.52M$40.52M
2020-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$40.52M+7.4%2026-03-02, From 2025-01-01
2024-12-31$37.74M+2.9%2026-03-02, From 2024-01-01
2023-12-31$36.68M-11.4%2025-03-07, From 2023-01-01
2022-12-31$41.42M+12.3%2024-03-27, From 2022-01-01
2021-12-31$36.89M+17.9%2023-03-30, From 2021-01-01
2020-12-31$31.30Mn/a2022-03-18, From 2020-01-01

Revenue at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Alpha Teknova, Inc. (TKNO)2025-12-31$40.52M+7.4%
Immucell Corp (ICCC)2025-12-31$27.64M+4.3%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$67.67M+16.9%
Aspira Women's Health Inc. (AWHL)2025-12-31$9.22M+0.4%
Anbio Biotechnology (NNNN)2025-12-31$8.65M+5.6%
Biomerica Inc (BMRA)2026-05-31$4.45M-16.2%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$4.05M+115.6%
Myriad Genetics Inc (MYGN)2025-12-31$824.50M-1.6%
Neogen Corp (NEOG)2026-05-31$870.40M-2.7%

Compare TKNO, ICCC, NTLA, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗